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A B S T R AC T
The diagnosis of food allergy is established in cases 
where an immediate allergic reaction has occurred 
in the last year to a clearly identifiable allergenic food 
combined with sensitisation to this allergenic food. In all 
other cases, a food challenge test is required to establish 
or reject the diagnosis of food allergy. Although the 
double-blind placebo-controlled food challenge (DBPCFC) 
test is considered the gold standard, false-positive 
and false-negative outcomes occur. The incidence of 
false-positive outcomes is unknown because the results 
of DBPCFC tests cannot be further confirmed by other 
tests. If possible, it is important to perform double-blind 
challenges with recipes that have been validated for 
blinding and to use challenge procedures that have been 
proven safe in clinical practice, in order to reduce the risk 
of unwanted false-positive and false-negative outcomes 
and severe challenge reactions. The national guideline 
of the Dutch Society of Allergology describes when 
challenges are indicated and contraindicated, how food 
challenges are best conducted and how patients could best 
be managed and followed-up after the challenge tests have 
been completed.
K E Y WOR DS
Double blind placebo controlled food challenge, Dutch 
guideline, food allergy
I N T RODUC T I ON
If the patient’s history concerning the ingestion of a 
particular allergenic food or information about the 
symptoms following ingestion or the time interval between 
ingestion and the beginning of the symptoms are lacking, 
not clear cut or not specific for an allergic reaction, 
determination of specific immunoglobulin E (IgE) may 
help to rule out an allergic cause. Absence of specific IgE 
in these cases indicates that the patients are probably not 
allergic to the ingested food because the specificity of 
this sensitisation test is very high. If, on the other hand, 
the patient has specific IgE to an allergen, the chance the 
patient is allergic to this allergen is more likely but yet not 
confirmed because the sensitivity of this test is in itself 
very low. This is because many people have specific IgE 
that is of no clinical relevance. In these cases a challenge 
test is the only way to ascertain the clinical relevance. The 
double-blind placebo controlled challenge (DBPCFC) is 
the best test available to establish the diagnosis of food 
allergy. Although the DBPCFC is the gold standard, 
false-positive, false-negative and inconclusive results, 
and undesired severe reactions do occur. A false-positive 
result indicates that the patient reacts convincingly during 
the challenge but is not allergic to the challenged food. 
377
NOV EMB E R  2 0 1 6 ,  V O L .  7 4 ,  N O .  9
The Netherlands Journal of Medicine
Van Maaren et al. Dutch guideline on food allergy.
A false-negative result indicates that the patient does not 
react during the challenge but is allergic. Whether the test 
result is false-negative or false-positive will only be known 
if patients report that they reacted during (re)introduction 
of the challenged food or that they did not react following 
accidental ingestion. Because patients have reported 
such reactions and because placebo reactions have been 
documented during placebo-controlled challenges, it is 
known that these unwanted results do exist. However, the 
incidence of these undesired results is not known.
A false-positive challenge test has a negative impact on 
the quality of life.1 A patient who avoids food has a poorer 
quality of life and may have a diet that lacks essential 
nutrients.2 Additionally, increasing scientific evidence 
suggests that delayed introduction of foods or unnecessary 
avoidance may increase the risk of acute allergic reactions 
on (re)introduction to these foods in atopic children.3 The 
danger of a false-negative test is obvious: the patient runs 
the risk of an allergic reaction during introduction when 
they may not be carrying emergency medication. 
By adjusting the number of challenge steps, the start dose 
and last dose, the time intervals and the stop criteria for 
termination of the challenge test or the proportion of open 
to double challenges, the numbers of false-positive results, 
false-negative results and undesired reactions change. The 
goal of this guideline is to explain how to minimise the 
risk of these adverse results while keeping the challenge 
test acceptable as a routine test. 
P L AC E  O F  S E N S I T I S A T I ON  T E S T S  I N 
D I AGNO S I NG  FO OD  A L L E RG Y
Sensitisation tests aim to detect specific IgE directed 
against an allergen. Specific IgE can be determined 
indirectly by a skin prick test or directly by a serological 
test. The result of a sensitisation test can be compared 
with the results of the gold standard, the DBPCFC. In this 
way the specificity and sensitivity can be determined. In 
general, the sensitivity of specific IgE tests with allergens 
is low, especially when the results are not combined with 
information from the patient’s history. 
Allergenic foods contain a mixture of different allergens. 
Skin prick tests with food or specific determinations of 
IgE give no information on which allergen the patient 
is sensitive to in this mixture. The individual allergens 
that are present in one food are called components by 
the manufacturer of a test to determine specific IgE to 
increasing numbers of individual allergens. This test 
is called component resolved diagnosis. With this test, 
one can discriminate between food-specific allergens 
that are associated with systemic reactions and some 
highly cross-reactive food-plant allergens such as those 
belonging to the pathogen-related family of proteins 10 
(PR10) and profilins that are associated with tolerance or 
relatively mild symptoms as itchy mouth confined to the 
oral cavity and throat (so called 'oral allergy complaints'). 
As a result, component resolved diagnosis testing has a 
higher specificity and sensitivity when used to diagnose 
allergy to foods that contain both types of allergens such 
as peanut and tree nuts, as compared with skin prick tests 
and serological tests with these foods, but not in e.g. milk 
that contains milk specific components.4 
The cut-off values of serological tests that can predict the 
negative or positive outcome of the food challenge test 
are of more clinical use than sensitivity and specificity of 
tests. If these positive and negative predictive values (PPV 
and NPV) can predict the outcome of the challenge test 
with high probability, a challenge test may not always be 
needed to establish presence or absence of allergy. If one 
could predict the negative outcome of a challenge test with 
100% certainty in patients that have specific IgE equal or 
below a certain cut-off value, challenges may no longer 
be needed in these patients. An NPV of 95% indicates 
that 5% of the patients who have a value equal to or below 
the cut-off value would react in a food challenge test. 
Advising patients who have a 5% chance of being allergic to 
introduce food based on a sensitisation test alone is usually 
not acceptable because some of them run a risk of a severe 
reaction in an unsupervised setting. 
High specific IgE cut-off values associated with a post-test 
probability of a positive outcome of a challenge test of 
100% are desirable but are likely to be applicable to only 
a relatively small number of patients. If a PPV of 95% is 
considered acceptable, a larger proportion of challenge tests 
would be redundant. However, even more modest cut-off 
values associated with correspondingly more modest 
PPVs have been found to differ between populations of 
different ages, and even from different centres. There are 
many possible explanations for these differences including 
differences in age and sex composition, geographical 
region, proportion of sensitised patients, all of which 
may influence prevalence and thus PPV. Moreover, the 
prevalence of food allergy can vary over time and therefore 
cut-off values associated with certain PPVs may change. 
As mentioned above, a new approach to serological testing 
is the component resolved diagnosis test, or determination 
of specific IgE to single allergens contained in foods. This 
has proved most successful in peanut allergy. Positive 
specific IgE tests to Ara h2, a major peanut specific 
allergen, is associated with an increased risk of clinical 
peanut allergy and, to a lesser extent, an increased risk of 
relatively severe reactions to peanuts. In several studies, 
PPVs of specific IgE against Ara h2 may be associated 
with PPVs as high as 95%. As expected, the cut-off value 
of Ara h2 with a PPV of 95% differs from one study to 
another. Published specific IgE cut-off values to different 
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allergens associated with high PPVs are thus of limited 
generalisability and as a result cannot currently replace 
challenge tests.5-7 
Aside from establishing the diagnosis of food allergy, 
the challenge test gives the patient some experience 
in recognising symptoms and improves health-related 
quality of life. Reactions and the amount of food protein 
eliciting them may not be extrapolated to accidental 
reactions because in real life other factors are operational 
that can influence the threshold level, such as the way 
the consumed food has been processed and the matrix in 
which it is present, the use of medication, the presence 
or absence of illness and co-factors such as exertion and 
alcohol. 
The Dutch guideline Task Force advises not to replace food 
challenges by sensitisation tests or component resolved 
diagnosis testing to establish the diagnosis of food allergy 
in patients who have never eaten the tested food, who did 
not react with convincing symptoms, who reacted more 
than one year before presentation, or who did not react to 
a clearly identifiable allergenic food. 
I N D IC AT IONS  A ND 
CON T R A I ND IC AT IONS
Challenge tests are indicated in the following cases:
• To establish the diagnosis of food allergy
• To evaluate if a patient has outgrown a food allergy that 
was established in the past
• To establish the clinical relevance of specific IgE to an 
allergenic food if patient history is indeterminate
• To educate a patient on which symptoms he may expect 
if he accidentally ingests the food and how to respond.
Absolute contraindications are:
• Uncontrolled asthma
• Unstable angina pectoris
• Severe chronic lung disease
• Pregnancy
• Fever.
Relative contraindications are present when factors 
associated with severe reactions or complications during 
challenge tests that negatively interfere with the treatment 
of a reaction or that hamper the interpretation of the 
challenge test are operational. There is no direct medical 
evidence that these factors truly prohibit a challenge 
procedure because in challenge studies patients who have 
a medical condition or use medication that could negatively 
affect the severity or treatment of a reaction (beta-agonists, 
ACE inhibitors and NSAIDs) or interpretation of 
the challenge test (systemic corticosteroids and 
antihistamines) are always excluded. Indirect evidence 
concerning potential risk factors of severe reactions during 
challenge tests are derived from studies of patients seen in 
the emergency room because of anaphylactic reactions or 
who have been treated with allergen immunotherapy and 
reacted severely to a subcutaneous injection.8,9 Because 
risk-augmenting medication can often temporarily be 
stopped or switched, or unfavourable conditions may often 
be treated prior to challenge or are of a temporary nature, 
it is rarely acceptable to undertake an oral food challenge 
when such risk factors are present, even if direct evidence 
of the increase in risk is lacking. 
If an unfavourable condition persists or medication cannot 
be stopped or switched, it is advised to consult or refer to 
a centre where an allergist who has extensive experience 
with food challenges under difficult circumstances and 
with high-risk challenges can supervise the procedure. 
Official criteria for these ‘allergy specialist centres’ have 
not been formalised, but the Task Force considers centres 
that meet the following criteria as such:
• Challenges are supervised by recognised allergists/
paediatric allergists 
• In these centres large numbers of challenge tests are 
performed
• The food challenge procedures are protocolised
• Tasks and responsibilities before, during and after the 
challenge test are clearly assigned 
• All amenities are present to treat anaphylaxis including 
intensive care facilities. 
OPEN  V S  D OU B L E - B L I N D  CH A L L E NGE S
The challenge test can be done in an open (open food 
challenge: OFC) or double-blind fashion (double-blind 
placebo-controlled challenge: DBPCFC). In an open 
challenge test the food may be administered in its native 
form. In a double-blind challenge, the challenge material 
is administered incrementally on two occasions. On one 
day, the food to be tested is given while being masked in a 
matrix food (for example in a slice of cake or drink), while 
on the other day only a matched placebo is given. The order 
of the days is randomised so that neither the patient nor 
anyone in contact with the patient knows on which day the 
placebo or the suspected food is given. 
Studies in which DBPCFCs are performed show that 
placebo reactions occur regularly. Generally these reactions 
consist of subjective symptoms or symptoms that appear 
more than two hours after the end of procedure, but 
sometimes they also consist of acute reactions with 
objective symptoms. In clinical practice, if we only use 
OFCs the outcome would be that a small unknown 
percentage of challenges ending with acute objective 
symptoms would be considered positive while actually 
being false-positive. Consequently some patients would be 
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incorrectly diagnosed as being allergic. If open challenges 
ending with subjective symptoms are also considered 
positive, it would result in a considerably larger percentage 
of false positive results. 
The potential negative influence of several of these factors 
can be minimised by blinding the procedure. The result 
from the administration of the suspected food is compared 
with that of the placebo before making the diagnosis. 
The test is considered positive if the patient reacts to the 
suspected food with symptoms constituting the agreed 
stop criteria and clearly more severe than to the placebo. 
Patients not reacting on either test day or with atypical or 
relatively mild reactions on the placebo day are considered 
test negative.10-12 
It is advised to choose an open challenge test if it is very 
likely that the patient is not allergic. If subjective or late 
symptoms are to be expected, if the patient has eczema, if 
the patients fears a severe reaction, or symptoms following 
an ingestion are different from what would be usually 
expected (e.g. urticaria instead of oral allergy complaints 
after eating an apple) the double-blind food challenge 
should always be the first choice. 
R I S K  O F  S E V E R E  R E AC T I ONS  A N D 
S A F E T Y  P R E C AU T I ONS
The percentage of a near-fatal or fatal anaphylaxis during 
oral food challenges is probably negligible in daily practice. 
In the literature no fatal reactions have been documented. 
The percentage of severe allergic reactions published in 
the literature reaches a maximum of 10% depending on 
how a severe reaction is defined and the characteristics 
of the patients who are challenged. It is believed that 
the percentage of anaphylaxis in the clinics where the 
members of the Task Force work is much lower than 
10%. This low percentage is likely due to the fact that 
challenges are performed with carefully selected patients 
by skilled and experienced personnel, and with procedures 
and up-dosing schedules that have been proven safe and 
reliable in clinical practice. 
In the Netherlands, allergists tend to categorise challenge 
tests into high- and low-risk challenges and take extra 
precautions when a high-risk challenge is performed. 
Despite this fact, no consistent predictors of a severe 
reaction during a challenge can be derived from published 
food challenge studies.13,14 All authorities agree that any 
patient with a previous life-threatening reaction to a 
food is a high-risk patient unless there is evidence of 
tolerance subsequent to the severe reaction. Nevertheless 
the majority of high-risk patients have only experienced 
mild reactions, and the Task Force felt the need for 
uniform criteria that would discern high- and low-risk 
challenges in patients without previous life-threatening 
reactions. Criteria were thus derived from retrospective 
studies in which the characteristics of patients visiting 
an emergency room because of accidental (near) fatal 
anaphylaxis were analysed.15 Patients in these studies 
have similar characteristics in different studies and these 
criteria are the same as those used to decide who needs to 
be prescribed an epinephrine auto-injector.16
The following criteria apply for high-risk challenges:
• If any combination of two of the following is present: 
 - Challenges with adolescents and young adults 
(≥ 12 years of age)
 - Challenges in patients with asthma or a previous 
asthmatic reaction to the food to be challenged
 - Challenge in a patient who has reacted to traces of 
the food to be challenged
 - A challenge test with a peanut or tree nut.
• A challenge test with a food to which the patient 
reacted severely in the past regardless the degree of 
sensitisation.
As a result of these criteria, a challenge test with a peanut 
or tree nut is a high-risk test if only one other criteria 
applies, while a challenge test involving other foods 
is considered high risk if two criteria are applicable. 
Challenge tests with fruit are considered low risk even if 
two risk factors are applicable. Challenge tests with a food 
to which the patient has had an anaphylactic reaction in 
the past are always considered high risk even if no other 
criterion is applicable and even if a fruit is challenged. 
If these criteria are used in daily practice, the chance 
of severe reactions during low-risk challenge tests is 
probably low but can never be completely excluded. For 
this reason the setting in which the challenge is performed 
must always be suitable to care for patients who have an 
anaphylactic shock and the supervising personal should 
always be prepared for such an event. Furthermore it is 
advised to only perform high-risk challenge tests in allergy 
specialist centres as indicated above. 
R E C I P E S  A N D  L O G I S T I C S  O F 
CH A L L E NGE  M AT E R I A L
To guarantee that the challenged food has been blinded 
appropriately, recipes should be used that have been 
validated for blinding. To validate recipes is a labour 
intensive procedure and in most studies that use 
‘double-blind’ challenge tests the recipes used are not 
validated. The recipes that are validated are summarised 
in the full text version of the guideline as are the other 
requirements for these recipes to make them acceptable to 
use them in challenge tests.17 
Recipes that are validated for blinding for double-blind 
challenge tests are available for the following allergenic 
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foods: cow’s milk, hen’s egg, soy milk, hazelnuts, peanut, 
cashew nut and wheat. Unfortunately, there are none for 
fish, shell fish, legumes other than soy and peanut, and 
seeds. These allergenic foods can thus only be challenged 
in an open fashion. Open challenges are usually best 
performed with food in its native form.18-20
CH A L L E NGE  D O S I NG  S CH EDU L E
The optimal challenge schedule meets the following 
criteria:
• The challenge procedure should be performed in half a 
working day so that sufficient observation time is left.
• The lowest dose administered is about the same as 
the lowest threshold dose on which an allergic patient 
is able to react to prevent large numbers of patients 
reacting (severely) to the first dose.
• The highest dose is similar to the amount of food an 
adult or child could consume at one time in daily life 
to prevent false-negative results due to an inadequate 
final dose.
• The incremental doses and time intervals in between 
two following doses should be chosen in such a way to 
prevent severe reactions because the time interval is too 
short or a dose gap is too large.
The first-mentioned criterion could conflict with the last if 
a safe procedure cannot be completed within office hours. 
Fortunately, a lot of experience has been acquired with 
recipes and up-dosing schedules that meet the criteria 
above. An interval between doses of 30 minutes has proven 
to be safe and practical, even though there is evidence 
showing that many patients probably react to cumulative 
rather than discrete doses. One of the limitations of the 
schedules currently in use may be that the last dose is not 
always high enough to rule out false-negative outcomes. 
Dosing schedules that have proven to be safe and practical 
have been shown to be quite similar for different foods 
when each dose step is expressed as the amount of protein 
of the allergenic food. As a result the same up-dosing 
schedule is advised for both open and double blind 
challenges independent of the food challenged. The 
ideal incremental dose sequence is mentioned in the full 
text version as are the adjustments that could be made 
depending on the food that needs to be challenged.17,21-23 
Even when the last dose is similar to an age-appropriate 
portion of the food, false-negative results are possible. 
This is known because some patients fail to successfully 
introduce the food because of reactions during 
introduction. The reasons for this are only partially 
known and include occurrence of enhancing co-factors 
during introduction, induction of short lived tolerance by 
the challenge procedure and matrix effects. Therefore, 
open challenges should be carried out to confirm negative 
DBPCFCs and are especially important following high-risk 
negative double-blind challenges or those where the final 
dose was less than a possible daily portion, or when the 
double-blind test is unexpectedly negative. 
S TOP  C R I T E R I A  A ND  I N T E R PR E TAT ION
It is generally felt that early termination of challenges 
with minimal symptoms will result in a greater number 
of false-positive test results. Conversely, late termination 
of challenges with clear objective symptoms will result 
in a greater number of severe reactions. Stop criteria for 
termination of the challenge test should be defined in 
such a way that the number of false-positive results and 
severe reactions can be kept to a minimum. Unfortunately 
it is not known which stop criteria are optimal because no 
studies exist in which the challenge tests with different 
stop criteria are compared. Therefore stop criteria are 
generally based on consensus and optimal stop criteria 
appropriate to the goals of the test centre should be 
ascertained in daily practice. Currently, it is deemed 
that objective stop criteria result in the lowest number 
of false-negative results and are still safe when used in 
studies. However, in daily practice it may not always be 
feasible to continue challenges until objective symptoms 
occur. 
In 2012 the PRACTALL Task Force published a set of stop 
criteria that are advocated by the American and European 
Societies of Allergology. The Task Force of the present 
guideline adopted and translated these stop criteria into 
Dutch to promote their implementation. Using uniform 
stop criteria will promote the comparability of the results 
of challenge tests wherever they are performed. The 
symptoms in the PRACTALL list are ordered according to 
organ system, e.g. gastrointestinal or lower airways, and 
the severity of the symptoms is graded (mild, moderate, 
severe). 
The PRACTALL stop criteria are not absolute. Based on the 
presence of a certain combination of specific symptoms 
and their severity it is more or less likely that the cause of 
the symptoms is allergic. This advice on when to stop and 
when to continue leaves room for the supervising allergist 
to decide if the challenge test day is positive or not (yet). 
If symptoms occur that are not enough to terminate the 
challenge it is advised to extend the time interval or to 
repeat the last administered dose. If an OFC ends with 
subjective, mild or moderate objective symptoms, or 
with other symptoms than what would be expected from 
the patient’s medical history, it is advised to perform a 
DBPCFC to confirm the allergy.8,24
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FO L L OW - U P  A F T E R  T H E  CH A L L E NGE
Performing challenge testing is only of value if such 
tests are followed up by successful reintroduction of 
foods which tested negatively or continued elimination 
of the challenged foods following positive tests. In case 
of a positive challenge result, the challenge is successful 
if the patient manages to avoid the food he reacted to 
and/or is capable of treating him/herself adequately 
following accidental exposures while maintaining a diet 
that is still varied and not lacking in essential nutrients. 
A negative challenge is successful if the patient manages 
to (re)introduce the food into the diet. From five published 
studies in which patients were asked by means of a 
questionnaire or an interview if they had introduced the 
tested food permanently it is known that up to a third do 
not manage to introduce the food for various reasons.25 
From a questionnaire sent by the Task Force to patients 
who underwent a food challenge test, it is known that 37% 
wished they had been followed up more effectively after the 
challenge test. From these data it may be concluded that 
follow-up after a challenge test may be improved and that 
good follow-up probably leads to better long-term results. 
Although there are no studies on the optimal form of 
follow-up for patients after a challenge test, the Task Force 
offers advice based on expert opinion and consensus. 
Following a negative challenge test it is advised to (re)
introduce foods with the help of an introduction schedule 
for home use. Such introduction schedules include an 
explanation on how a patient can introduce the food over 
the course of a few days so that ultimately he or she feels 
confident eating a normal portion. In the event the patient 
experiences symptoms attributable to ingesting the food 
being introduced, contact with an allergist, dietitian or an 
experienced allergy nurse should be sought to discuss if 
the introduction should be continued with or without an 
adjustment of the schedule, or stopped. It is also advised to 
contact the patient a few months after the introduction to 
ask if the food is now being eaten regularly. If consumption 
of the food has been stopped, the reason for this may be 
ascertained and assistance offered to solve the problem.26 
Patients in whom the food allergy has been confirmed 
should be instructed how to read labels, how to deal with 
advisory labelling (i.e. ‘may contain’) and be prescribed 
an epinephrine auto-injector where appropriate. Such 
a prescription should be accompanied by written and 
repeated oral instructions on how to treat a reaction in the 
event of accidental ingestion. Especially if the allergenic 
food cannot be easily avoided and/or if the food is part of 
the staple diet, such as wheat or milk, it is advised to refer 
the patient to an experienced dietitian. The dietitian can 
instruct the patient on the correct interpretation of food 
labels, find alternative ingredients for recipes and prescribe 
supplements if the diet lacks essential nutrients. The 
dietician may also support the patient and family members 
in dealing with the food allergy. 
I N S T RUC T I ON  A N D  P R AC T I C A L 
A DV I C E
In the last chapter of the guideline some practical advice 
is given on topics for which no evidence exists. This advice 
is based on expert opinion and consensus of the members 
of the Task Force. 
The Task Force deems it important that one supervisor is 
appointed to be responsible for the decision to continue or 
terminate the challenge test and determine and administer 
the treatment in the event of a reaction. This supervisor 
should be an experienced paediatrician specialised in 
allergies for challenges that are performed in children and 
an experienced allergist or dermatologist for challenges 
performed in adults. During the challenge test the patient 
should always be monitored by healthcare providers who 
are trained to recognise allergic symptoms and are capable 
of starting treatment and supporting advanced treatment 
of a severe anaphylactic reaction.
The full text of the guideline provides information on how 
to instruct the patient, and how long the patient should 
be observed depending on if the patient reacted and the 
severity of the reaction.
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